Literature DB >> 27792289

Multiple sclerosis animal models: a clinical and histopathological perspective.

Markus Kipp1, Stella Nyamoya1,2, Tanja Hochstrasser1, Sandra Amor3,4.   

Abstract

There is a broad consensus that multiple sclerosis (MS) represents more than an inflammatory disease: it harbors several characteristic aspects of a classical neurodegenerative disorder, that is, damage to axons, synapses and nerve cell bodies. While we are equipped with appropriate therapeutic options to prevent immune-cell driven relapses, effective therapeutic options to prevent the progressing neurodegeneration are still missing. In this review article, we will discuss to what extent pathology of the progressive disease stage can be modeled in MS animal models. While acute and relapsing-remitting forms of experimental autoimmune encephalomyelitis (EAE), which are T cell dependent, are aptly suited to model relapsing-remitting phases of MS, other EAE models, especially the secondary progressive EAE stage in Biozzi ABH mice is better representing the secondary progressive phase of MS, which is refractory to many immune therapies. Besides EAE, the cuprizone model is rapidly gaining popularity to study the formation and progression of demyelinating CNS lesions without T cell involvement. Here, we discuss these two non-popular MS models. It is our aim to point out the pathological hallmarks of MS, and discuss which pathological aspects of the disease can be best studied in the various animal models available.
© 2016 International Society of Neuropathology.

Entities:  

Keywords:  EAE; PPMS; SPMS; cuprizone; disability; disease progression; multiple sclerosis; neurodegeneration; treatment

Mesh:

Substances:

Year:  2017        PMID: 27792289     DOI: 10.1111/bpa.12454

Source DB:  PubMed          Journal:  Brain Pathol        ISSN: 1015-6305            Impact factor:   6.508


  62 in total

1.  Retrospective Analysis of the Effects of Identification Procedures and Cage Changing by Using Data from Automated, Continuous Monitoring.

Authors:  Maria A Lim; Erwin B Defensor; Jordan A Mechanic; Puja P Shah; Evelyn A Jaime; Clifford R Roberts; David L Hutto; Laura R Schaevitz
Journal:  J Am Assoc Lab Anim Sci       Date:  2019-02-14       Impact factor: 1.232

2.  Aged hind-limb clasping experimental autoimmune encephalomyelitis models aspects of the neurodegenerative process seen in multiple sclerosis.

Authors:  Lindsay S Cahill; Monan Angela Zhang; Valeria Ramaglia; Heather Whetstone; Melika Pahlevan Sabbagh; Tae Joon Yi; Laura Woo; Thomas S Przybycien; Marina Moshkova; Fei Linda Zhao; Olga L Rojas; Josephine Gomes; Stefanie Kuerten; Jennifer L Gommerman; John G Sled; Shannon E Dunn
Journal:  Proc Natl Acad Sci U S A       Date:  2019-10-22       Impact factor: 11.205

3.  Visualization of the Breakdown of the Axonal Transport Machinery: a Comparative Ultrastructural and Immunohistochemical Approach.

Authors:  Sebastian Rühling; Franziska Kramer; Selina Schmutz; Sandra Amor; Zhan Jiangshan; Christoph Schmitz; Markus Kipp; Tanja Hochstrasser
Journal:  Mol Neurobiol       Date:  2018-09-21       Impact factor: 5.590

4.  Activating transcription factor 6α deficiency exacerbates oligodendrocyte death and myelin damage in immune-mediated demyelinating diseases.

Authors:  Sarrabeth Stone; Shuangchan Wu; Stephanie Jamison; Wilaiwan Durose; Jean Pierre Pallais; Wensheng Lin
Journal:  Glia       Date:  2018-02-13       Impact factor: 7.452

5.  Adenosine Promotes the Recovery of Mice from the Cuprizone-Induced Behavioral and Morphological Changes while Effecting on Microglia and Inflammatory Cytokines in the Brain.

Authors:  Jinling Zhang; Liu Yang; Zeman Fang; Jiming Kong; Qingjun Huang; Haiyun Xu
Journal:  J Neuroimmune Pharmacol       Date:  2018-08-01       Impact factor: 4.147

6.  NF-κB Activation Protects Oligodendrocytes against Inflammation.

Authors:  Sarrabeth Stone; Stephanie Jamison; Yuan Yue; Wilaiwan Durose; Ruth Schmidt-Ullrich; Wensheng Lin
Journal:  J Neurosci       Date:  2017-08-23       Impact factor: 6.167

7.  Toll-Like Receptor 2-Mediated Glial Cell Activation in a Mouse Model of Cuprizone-Induced Demyelination.

Authors:  Stefan Esser; Larissa Göpfrich; Kai Bihler; Eugenia Kress; Stella Nyamoya; Simone C Tauber; Tim Clarner; Matthias B Stope; Thomas Pufe; Markus Kipp; Lars-Ove Brandenburg
Journal:  Mol Neurobiol       Date:  2017-12-29       Impact factor: 5.590

8.  Temporal and Spatial Dynamics of Astroglial Reaction and Immune Response in Cuprizone-Induced Demyelination.

Authors:  Jun An; Jun-Jun Yin; Yan He; Ruo-Xuan Sui; Qiang Miao; Qing Wang; Jie-Zhong Yu; Jing-Wen Yu; Fu-Dong Shi; Cun-Gen Ma; Bao-Guo Xiao
Journal:  Neurotox Res       Date:  2019-11-13       Impact factor: 3.911

9.  Formyl Peptide Receptor 1-Mediated Glial Cell Activation in a Mouse Model of Cuprizone-Induced Demyelination.

Authors:  Kai Bihler; Eugenia Kress; Stefan Esser; Stella Nyamoya; Simone C Tauber; Tim Clarner; Matthias B Stope; Thomas Pufe; Lars-Ove Brandenburg
Journal:  J Mol Neurosci       Date:  2017-05-02       Impact factor: 3.444

10.  Deregulation of the endocannabinoid system and therapeutic potential of ABHD6 blockade in the cuprizone model of demyelination.

Authors:  Andrea Manterola; Ana Bernal-Chico; Raffaela Cipriani; Manuel Canedo-Antelo; Álvaro Moreno-García; Mar Martín-Fontecha; Fernando Pérez-Cerdá; María Victoria Sánchez-Gómez; Silvia Ortega-Gutiérrez; J Mark Brown; Ku-Lung Hsu; Benjamin Cravatt; Carlos Matute; Susana Mato
Journal:  Biochem Pharmacol       Date:  2018-08-01       Impact factor: 5.858

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.